Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
Status:
Withdrawn
Trial end date:
2019-05-10
Target enrollment:
Participant gender:
Summary
This is a randomized, controlled, open-label, multicenter study to evaluate the safety,
tolerability, pharmacokinetic (PK), and adenovirus (AdV) antiviral activity of multiple
ascending doses of IV brincidofovir (BCV). Approximately 30 eligible subjects will be
sequentially enrolled into 1 of 3 planned cohorts. Within each cohort, subjects will be
randomized in a 4:1 ratio to receive IV BCV dosed twice weekly (BIW) (on Days 1, 4, 8, and
11) or to receive investigator-assigned standard of care (SoC).